PB-CD19 CAR-T / Kyoto Prefectural University of Medicine - LARVOL DELTA

PiggyBac Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function. (PubMed, Front Immunol) - "To further investigate the favorable phenotype of PB-CD19 CAR-T cells, we generated PB-CD19 CAR-T cells from CD45RA and CD45RA peripheral blood mononuclear cells (PBMCs) (RA CAR and RA CAR, respectively), and compared their phenotypes and antitumor activity...Our results suggest that PB-mediated RA CAR-T cells exhibit a memory-rich phenotype and superior antitumor function, thus CD45RA PBMCs might be considered an efficient starting material for PB-CAR-T cell manufacturing. This novel approach will be beneficial for effective treatment of B cell malignancies."

CAR T-Cell Therapy • IO biomarker • Journal • Gene Therapies • Oncology • B3GAT1 • CCR7 • CD19 • CD8 • PD-1

Piggybac Transposon Mediated CD19 CAR-T Cells Derived from CD45RA-Positive PBMCs Possess Potent and Sustained Antileukemic Function (ASH 2021) - "Our results suggest that PB-mediated RA+ CAR-T cells exhibit memory-rich phenotype and superior antitumor function, thereby indicating the usefulness of CD45RA+ PBMC as a starting material of PB-CAR-T cells."

CAR T-Cell Therapy • IO biomarker • Oncology • CCR7 • CD19 • CD57 • CD8 • PD-1